Compare INUV & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INUV | CVM |
|---|---|---|
| Founded | N/A | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 21.4M |
| IPO Year | 1996 | 1996 |
| Metric | INUV | CVM |
|---|---|---|
| Price | $1.26 | $1.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | 142.2K | ★ 357.5K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.00 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $86,209,305.00 | $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.89 | N/A |
| P/E Ratio | $9.54 | ★ N/A |
| Revenue Growth | 2.88 | ★ 65.45 |
| 52 Week Low | $1.21 | $0.89 |
| 52 Week High | $6.27 | $13.48 |
| Indicator | INUV | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 31.45 | 34.15 |
| Support Level | N/A | $0.94 |
| Resistance Level | $2.01 | $1.59 |
| Average True Range (ATR) | 0.10 | 0.11 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 16.13 | 17.31 |
Inuvo Inc is an advertising technology and services company that has developed and commercialized large language generative artificial intelligence (AI) for modeling media audiences. Its products and services include ValidClick and IntentKey. The company's platforms identify and message online audiences for any product or service across devices, channels, and formats, including video, mobile, connected TV, display, social, and native. It has clients from various industries that include retail, automotive, insurance, health care, technology, telecommunications and finance. Inuvo's revenue is derived from the placement of digital advertising throughout devices, websites, applications and browsers across social, search and programmatic advertising channels.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.